Krishna Bhat, Ph.D.
The overarching goals of the Bhat laboratory is to understand the molecular alterations that underlie adult brain tumors and identify novel therapeutic targets and biomarkers to eliminate this disease.
Dr. Bhat Lab
University of Texas at MD Anderson Cancer Center
2130 W Holcombe Blvd,
Glioblastoma (GBM) is the most common and aggressive adult brain tumor, afflicting approximately18,000 patients in the United States every year. After surgery, GBM patients are treated uniformly with concurrent chemotherapy and radiation, which is the standard of care.
Championed by the efforts of The Cancer Genome Atlas (TCGA), GBM is one of the most molecularly annotated of all cancer types. These steps, however, have not translated into clinical benefit as GBM has remained one of the most recalcitrant cancers with a median survival of only 12-15 months. Unlike other cancers, targeted therapies or “personalized medicine” approaches as well as immunotherapies have failed to improve outcome in GBM and therefore novel strategies are urgently needed to combat this disease.
Another major challenge in the treatment of patients with GBM is the lack of predictive biomarkers and the inability to provide longitudinal monitoring during therapy and during recurrence.
The Bhat laboratory takes multipronged approaches to address these areas of unmet need for brain tumors.